title: Antibacterial properties of a glycolipid-rich extract and active principle from Nunavik collections of the macroalgae Fucus evanescens C. Agardh (Fucaceae).
abstract: This study investigated the antibacterial activity of glycolipid-rich extracts of the brown macroalga Fucus evanescens in cell culture. Accessions were collected on the Arctic coast of Ungava Bay, Nunavik, Quebec. The crude ethyl acetate extract of these accessions showed strong antibacterial activity (≥4 log(10) cfu) against Hemophilus influenzae , Legionella pneumophila , Propionibacterium acnes (ATCC and clinical isolate), and Streptococcus pyogenes at 100 µg/mL. This algal extract inhibited by 3 log(10) Clostridium difficile and methicillin-resistant Staphylococcus aureus , whereas Bacillus cereus , Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa were not significantly affected. Further investigations of the activity of a glycolipid-rich fraction, extracted with dichloromethane, against Propionibacterium acnes showed an MIC(100) of 50 µg/mL, with an inhibition of more than 99% at only 7.8 µg/mL. The main active compound, a β-d-galactosyl O-linked glycolipid, was synthesized for the bioassay and showed an MIC(100) of 50 µg/mL but lost its activity more quickly with only 50% of inhibition at 12.5 µg/mL. Therefore, the semipurified F. evanescens extract could be a good choice for future research into the development of alternative treatments for acne therapy.
authors.affiliation: Department of Biology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
authors.forename: Virginie
authors.initials: V
authors.lastname: Treyvaud Amiguet
authors.forename: Linda E
authors.initials: LE
authors.lastname: Jewell
authors.forename: Halimasadia
authors.initials: H
authors.lastname: Mao
authors.forename: Manju
authors.initials: M
authors.lastname: Sharma
authors.forename: James B
authors.initials: JB
authors.lastname: Hudson
authors.forename: Tony
authors.initials: T
authors.lastname: Durst
authors.forename: Marc
authors.initials: M
authors.lastname: Allard
authors.forename: Guy
authors.initials: G
authors.lastname: Rochefort
authors.forename: John Thor
authors.initials: JT
authors.lastname: Arnason
mesh_terms: D000152:Acne Vulgaris; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D061006:Bays; D001688:Biological Products / Q000378:metabolism / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D044645:Fucus / Q000378:metabolism*; D006193:Haemophilus influenzae / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D011425:Propionibacterium acnes / Q000187:drug effects / Q000254:growth & development; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D011792:Quebec; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D001688:Biological Products